


Claims.

1. An (indol-3-yl)-heterocycle derivative having the general Formula I



5 wherein

A represents a 5-membered aromatic heterocyclic ring, wherein X₁, X₂ and X₃ are independently selected from N, O, S and CR;

R is H or (C₁₋₄)alkyl; or

R, when present in X₂ or X₃, may form together with R₃ a 5-8 membered ring;

10 R₁ is a 5-8 membered saturated carbocyclic ring, optionally containing a heteroatom selected from O and S;

R₂ is H, CH₃ or CH₂-CH₃; or

R₂ is joined together with R₇ to form a 6-membered ring, optionally containing a heteroatom selected from O and S, and which heteroatom is bonded to the 7-position of the indole ring;

15 R₃ and R₄ are independently H, (C₁₋₆)alkyl or (C₃₋₇)cycloalkyl, the alkyl groups being optionally substituted with OH, (C₁₋₄)alkyloxy, (C₁₋₄)alkylthio, (C₁₋₄)alkylsulfonyl, CN or halogen; or

20 R₃ together with R₄ and the N to which they are bonded form a 4-8 membered ring optionally containing a further heteroatom selected from O and S, and which is optionally substituted with OH, (C₁₋₄)alkyl, (C₁₋₄)alkyloxy, (C₁₋₄)alkyloxy-(C₁₋₄)alkyl, or halogen; or

25 R₃ together with R₅ forms a 4-8 membered ring optionally containing a further heteroatom selected from O and S, and which is optionally substituted with OH, (C₁₋₄)alkyl, (C₁₋₄)alkyloxy, (C₁₋₄)alkyloxy-(C₁₋₄)alkyl, or halogen; or

R₃ together with R, when present in X₂ or X₃, forms a 5-8 membered ring;

R₅ is H or (C₁₋₄)alkyl; or

R_5 together with R_3 forms a 4-8 membered ring optionally containing a further heteroatom selected from O and S, and which is optionally substituted with OH, (C_{1-4})alkyl, (C_{1-4})alkyloxy, (C_{1-4})alkyloxy- (C_{1-4})alkyl, or halogen;

R_5' is H or (C_{1-4})alkyl;

5 R_6 represents 1-3 substituents independently selected from H, (C_{1-4})alkyl, (C_{1-4})-alkyloxy, CN and halogen;

R_7 is H, (C_{1-4})alkyl, (C_{1-4})alkyloxy, CN or halogen; or

R_7 is joined together with R_2 to form a 6-membered ring, optionally containing a further heteroatom selected from O and S, and which heteroatom is bonded to the

10 7-position of the indole ring; or a pharmaceutically acceptable salt thereof.

2. The (indol-3-yl)-heterocycle derivative of claim 1, wherein R_2 is H or is joined together with R_7 to form a 6-membered ring, optionally containing a heteroatom selected from O and S, and which atom is bonded to the 7-position of the indole

15 ring.

3. The (indol-3-yl)-heterocycle derivative of claim 1 or 2, wherein R , R_5 , R_5' and R_6 are H.

20 4. The (indol-3-yl)-heterocycle derivative of any one of claims 1-3, wherein R_1 is cyclohexyl or tetrahydropyranyl.

5. The (indol-3-yl)-heterocycle derivative of any one of claims 1-4 where the heterocycle A is 1,2,4-oxadiazole (X_1 is N, X_2 is O, X_3 is N), 1,2,4-thiadiazole (X_1 is N, X_2 is S, X_3 is N) or thiazole (X_1 is S, X_2 is CR, X_3 is N).

25 6. The (indol-3-yl)-heterocycle derivative of claim 1 which is selected from:

- 7-Chloro-3-(5- $\{[N\text{-ethyl-}N\text{-}(2\text{-methoxyethyl})\text{amino}]\text{methyl}\}$ -[1,2,4]-thiadiazol-3-yl)-1-(tetrahydropyran-4-yl)methyl-1*H*-indole;
- 30 - 7-Chloro-3- $\{5\text{-}[(\text{pyrrolidin-1-yl})\text{methyl}]\text{-}[1,2,4]\text{-thiadiazol-3-yl}\}$ -1-(tetrahydropyran-4-yl)methyl-1*H*-indole;
- 7-Chloro-3-(5- $\{[N\text{-ethyl-}N\text{-}(2\text{-hydroxyethyl})\text{amino}]\text{methyl}\}$ -[1,2,4]-thiadiazol-3-yl)-1-(tetrahydropyran-4-yl)methyl-1*H*-indole;
- 35 - 7-Chloro-3-(4- $\{[N\text{-}(2\text{-hydroxyethyl})\text{-}N\text{-isopropylamino}]\text{methyl}\}$ -[1,3]-thiazol-2-yl)-1-(tetrahydropyran-4-yl)methyl-1*H*-indole;
- 7-Chloro-3-(4- $\{[N\text{-ethyl-}N\text{-}(2\text{-hydroxyethyl})\text{amino}]\text{methyl}\}$ -[1,3]-thiazol-2-yl)-1-(tetrahydropyran-4-yl)methyl-1*H*-indole;

- 7-Chloro-3-(4-{[N-(2-methoxyethyl)-N-methylamino]methyl}-[1,3]thiazol-2-yl)-1-(tetrahydropyran-4-yl)methyl-1*H*-indole;
- 7-Chloro-3-{5-[(2,2-dimethyl-pyrolidin-1-yl)methyl]-[1,2,4]oxadiazol-3-yl}-1-(tetrahydropyran-4-yl)methyl-1*H*-indole;

5 or a pharmaceutically acceptable salt thereof.

7. The (indol-3-yl)-heterocycle derivative of any one of claims 1-6 for use in therapy.

8. A pharmaceutical composition comprising an (indol-3-yl)-heterocycle derivative of
10 any one of claims 1-6 in admixture with pharmaceutically acceptable auxiliaries.

9. Use of an (indol-3-yl)heterocycle derivative of Formula I as defined in claim 1, in
the preparation of a medicament for the treatment of pain.

15 10. A method of treatment of pain such as peri-operative pain, chronic pain,
neuropathic pain, cancer pain and pain and spasticity associated with multiple
sclerosis, by administering to a patient in need thereof a therapeutically effective
amount of an (indol-3-yl)-heterocycle derivative of any one of claims 1-6.